PP1493

DRUG2 trials

Sponsors

Phaxiam Therapeutics

Conditions

Hip or Knee prosthetic joint infection due to Staphylococcus aureusknee or hip prosthetic joint infection (PJI) due to Staphylococcus aureuswith the indication of DAIR and Suppressive Antibiotics Therapy (SAT)

Phase 2

PhagoDAIR I : A Pilot, Multicenter, Randomized, Non Comparative, Double-Blind Study of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated with DAIR and Antibiotic Therapy.

CompletedCTIS2024-516207-17-00

Phaxiam Therapeuticsknee or hip prosthetic joint infection (PJI) due to Staphylococcus aureus, with the indication of DAIR and Suppressive Antibiotics Therapy (SAT)

Start: 2022-06-15End: 2025-04-08Target: 29Updated: 2025-03-24

A Phase II Proof of Concept Multicenter, Randomized, Double-Blind Study to assess the safety and efficacy of Phage Therapy in Patients with Hip or Knee Prosthetic Joint Infection due to Staphylococcus aureus Treated by DAIR

Not yet recruitingCTIS2024-516555-40-00

Phaxiam TherapeuticsHip or Knee prosthetic joint infection due to Staphylococcus aureus

Target: 51Updated: 2025-03-24